Loading...
•
Sep 30, 2020
Wave Life Sciences Q3 2020 Earnings Report
Wave Life Sciences announced its Q3 2020 financial results and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $33.1 million for the third quarter of 2020. The company's cash runway is expected to extend into the second quarter of 2023, bolstered by recent equity financing.
PRECISION-HD1 and PRECISION-HD2 clinical trial results and initial OLE data are expected in Q1 2021.
Dosing in three new clinical trials with novel compounds incorporating PN chemistry is expected in 2021.
Alpha-1 antitrypsin deficiency was announced as the first ADAR editing program.
The balance sheet was strengthened with equity financing, extending the cash runway into Q2 2023.
Forward Guidance
Wave Life Sciences expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...